Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience

Jose V. Forero, MD, Paula A. Lengerke Diaz, MD, Eider F. Moreno Cortes, MD, Megan Melody, MD, Allison C. Rosenthal, D.O., Mohamed A. Kharfan-Dabaja, MDMBA, Januario E. Castro, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143168

Published: 2020

Journal Articles

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Paula A. Lengerke Diaz, MD, Michael Y. Choi, MD, Eider F. Moreno Cortes, MD, Jose V. Forero, MD, Juliana Velez-Lujan, PhD, Carlos I. Amaya-Chanaga, MD, Thomas Kipps, MDPhD, Januario E. Castro, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-143473

Published: 2020

Journal Articles

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

Jae H. Park, MD, Nitin Jain, MD, Andy Chen, MDPhD, Joseph P. McGuirk, DO, Monica Diaz, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Januario E. Castro, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142423

Published: 2020

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Eider F Moreno Cortes, MD, Caleb K Stein, PhD, Paula A Lengerke Diaz, MD, Cesar A Ramirez-Segura, BS, PhD, Januario E. Castro, MD

Blood (2019) 134 (Supplement_1): 5629.

https://doi.org/10.1182/blood-2019-132273

Published: 2019

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

The Status of Multiple Myeloma in Colombia: First Report of the Colombian Registry for Hemato-Oncological Diseases (RENEHOC). Asociacion Colombiana De Hematologia y Oncologia (ACHO)

Virginia Abello, MD, Henry Idrobo, Claudia Lucia Sossa, Kenny Mauricio Galvez, MD, Domingo Saavedra, Maria Helena Solano, MD, Rigoberto Gomez, Lina Gaviria, MD, Jheremy Reyes, MD, Monica Osuna, Luis Antonio Salazar, MD, Angela María Peña, MD, Claudia Patricia Casas, MD, Daniel Espinosa, MD, Paula A Lengerke Diaz, MD, Januario E. Castro, MD

Blood (2018) 132 (Supplement 1): 5597.

https://doi.org/10.1182/blood-2018-99-114927

Published: 2018

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Juliana Velez Lujan, BS,PhD, Michael Y. Choi, MD, Chaja Jacobs, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2018-99-118990

Published: 2018

Journal Articles

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Juliana Velez Lujan, BS,PhD, Chaja Jacobs, MD, Paula A Lengerke Diaz, MD, Eider F Moreno-Cortes, MD, Cesar A Ramirez-Segura, BS, PhD, Michael Y. Choi, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD

Blood (2018) 132 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2018-99-119523

Published: 2018

Journal Articles

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Januario E Castro, MD, Carlos I. Amaya-Chanaga, MD, Juliana Velez Lujan, BS,PhD, Michael Choi, MD, Colin McCarthy, BS, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 1730.

https://doi.org/10.1182/blood.V130.Suppl_1.1730.1730

Published: 2017

Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 829.

https://doi.org/10.1182/blood.V130.Suppl_1.829.829

Published: 2017

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Carlos I. Amaya-Chanaga, MD, Michael Y. Choi, MD, Natalie Nguyen, B.Sc, Elizabeth DeVore, B.Sc, Colin MacCarthy, B.Sc, Jacqueline Hilger-Rolfe, PhD, M.S., Thomas J. Kipps, MD, PhD, Januario E. Castro, MD

Blood (2016) 128 (22): 2048.

https://doi.org/10.1182/blood.V128.22.2048.2048

Published: 2016

Journal Articles

A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, MD, Michael Y. Choi, MD, Carlos I. Amaya-Chanaga, MD, Natalie Nguyen, B.Sc, Colin MacCarthy, B.Sc, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 2051.

https://doi.org/10.1182/blood.V128.22.2051.2051

Published: 2016

Journal Articles

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Carla Casulo, MD, Jia Ruan, MD PhD, Nam H. Dang, MD PhD, Lia Gore, MD, Catherine Diefenbach, MD, Anne W Beaven, MD, Januario E. Castro, MD, Pierluigi Porcu, MD, Leonardo Faoro, MD, Jakob Dupont, MD, Ann Kapoun, PhD, Min Wang, PhD, Kristin McGuire, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 5108.

https://doi.org/10.1182/blood.V128.22.5108.5108

Published: 2016

Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Blood (2016) 128 (22): LBA-6.

https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6

Published: 2016

Journal Articles

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Jian Yu, PhD, Reilly L Kidwell, BS, BA, CCRC, Laura Z. Rassenti, PhD, Charlene Gutierrez, Susette Gorak, Tiffany Juarez, PhD, Emily Pittman, PhD, Hongying Li, PhD, Karen Messer, PhD, Charles Prussak, PhD, Januario E. Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 3224.

https://doi.org/10.1182/blood.V128.22.3224.3224

Published: 2016

Journal Articles

A Phase Ib/II Study of Combined Obinutuzumab and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, MD, Michael Y. Choi, MD, Carlos I. Amaya-Chanaga, MD, Natalie Nguyen, B.Sc, Amine Ale-Ali, PharmD, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 4160.

https://doi.org/10.1182/blood.V126.23.4160.4160

Published: 2015

Journal Articles

Targeting the CXCR4-CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia

Manoj K. Kashyap, PhD, Carlos I. Amaya-Chanaga, MD, Deepak Kumar, PhD, Michael Y. Choi, MD, Laura Z. Rassenti, PhD, Amine Ale-Ali, PharmD, Shu-Hui Liu, PhD, Tod Smeal, Valeria Fantin, PhD, Thomas J. Kipps, MD, PhD, Flavia Pernasetti, Januario E. Castro, MD

Blood (2015) 126 (23): 4162.

https://doi.org/10.1182/blood.V126.23.4162.4162

Published: 2015

NARROW

Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

The Status of Multiple Myeloma in Colombia: First Report of the Colombian Registry for Hemato-Oncological Diseases (RENEHOC). Asociacion Colombiana De Hematologia y Oncologia (ACHO)

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

A Phase Ib/II Study of Combined Obinutuzumab and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Targeting the CXCR4-CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only